OliX Pharmaceuticals (226950.KQ) Stock Price
OliX Pharmaceuticals Price
Revenue has compounded at 49.6% per year over the past 9 years to 14.67 B KRW. OliX Pharmaceuticals's net margin stands at -107.3%, up from -808.7% several years earlier.
OliX Pharmaceuticals stock price
OliX Pharmaceuticals business model & stock analysis
Frequently asked questions about OliX Pharmaceuticals
Converted at the current exchange rate, the OliX Pharmaceuticals share trades at 78.47 EUR (118,000.00 KRW).
The OliX Pharmaceuticals share (226950.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (226950.KQ).
The expected revenue of OliX Pharmaceuticals is 8.00 B KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of OliX Pharmaceuticals is -30.44 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of OliX Pharmaceuticals is currently -78.68. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the OliX Pharmaceuticals stock.
The price-to-sales ratio (P/S) of OliX Pharmaceuticals is currently 299.43. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the OliX Pharmaceuticals stock.
The Eulerpool Quality Score for OliX Pharmaceuticals is 3/10.
The ISIN of OliX Pharmaceuticals is KR7226950004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of OliX Pharmaceuticals is 226950.KQ. The ticker symbol is used to trade OliX Pharmaceuticals shares on the stock exchange.
OliX Pharmaceuticals stock
OliX Pharmaceuticals Peer Group
OliX Pharmaceuticals Ticker
OliX Pharmaceuticals FIGI
All fundamentals and in-depth analysis of OliX Pharmaceuticals
Our stock analysis for OliX Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OliX Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.